The sigma agonist 1,3-di-o-tolyl-guanidine directly blocks SK channels in dopaminergic neurons and in cell lines.
Small conductance Ca(2+)-activated K(+) (SK) channels are widely expressed in the brain and underlie medium-duration afterhyperpolarizations (mAHPs) in many types of neurons. It was recently reported that the activation of sigma-1 (sigma(1)) receptors inhibits SK currents in rat hippocampus. Because many interactions between sigma receptors and brain dopaminergic systems have been reported, we set out to examine putative effects of sigma receptor ligands on the SK mediated mAHP in midbrain dopaminergic neurons. We found that 1,3-di-o-tolyl-guanidine (DTG) inhibited the mAHP in a concentration-dependent manner (approximately 60% inhibition at 100 microM), while other sigma receptor agonists (carbetapentane, (+)-SKF10047 and PRE-084) had little effect. Moreover, the effect of DTG was not affected by high concentrations of the sigma(1) receptor antagonist BD 1047. A role for sigma(2) receptors could also be excluded by the lack of effect of the sigma(2) receptor ligand 5-bromo-tetrahydroisoquinolinylbenzamide. These results argue against a coupling of sigma receptors to SK channels in dopaminergic neurons. We next hypothesized that DTG could directly block the channel. This hypothesis was tested in HEK-293 cells which were transiently transfected with rSK2 or hSK3 subunits. DTG inhibited the current flowing through both subtypes with mean IC(50)s approximately 200 microM. This action was also unaffected by BD 1047. Other sigma receptor ligands had little or no effect. We conclude that DTG directly blocks SK channels. This pharmacological action may be important to consider in future experimental settings.
Lamy
Cédric
C
Laboratory of Pharmacology, GIGA-Neurosciences, University of Liège, B-4000 Sart-Tilman/Liège 1, Belgium.
Scuvée-Moreau
Jacqueline
J
Dilly
Sébastien
S
Liégeois
Jean-François
JF
Seutin
Vincent
V
D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D001030:Apamin / Q000494:pharmacology; D002460:Cell Line; D004298:Dopamine / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D006146:Guanidines / Q000494:pharmacology*; D066298:In Vitro Techniques; D008024:Ligands; D008297:Male; D009474:Neurons / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism*; D018408:Patch-Clamp Techniques; D026902:Potassium Channel Blockers / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D017480:Receptors, sigma / Q000819:agonists*; D051640:Small-Conductance Calcium-Activated Potassium Channels / Q000037:antagonists & inhibitors*
D006146:Guanidines; D008024:Ligands; D026902:Potassium Channel Blockers; D017480:Receptors, sigma; D051640:Small-Conductance Calcium-Activated Potassium Channels; D001030:Apamin; C050232:1,3-ditolylguanidine; D004298:Dopamine